These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32372672)

  • 1. A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: a case report and literature review.
    Zhang J; Wu L; Liu J; Lin M
    Immunotherapy; 2020 Jun; 12(8):555-561. PubMed ID: 32372672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
    Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
    J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrahepatic Cholangiocarcinoma with High Microsatellite Instability and Tumor Mutation Burden That Responded Significantly to Pembrolizumab but Perforated within a Short Period.
    Yamazaki S; Kubota K; Shimizu A; Notake T; Umemura K; Kamachi A; Goto T; Tomida H; Yamashita N; Sato M; Kanno H; Soejima Y
    Intern Med; 2024 Apr; 63(8):1105-1112. PubMed ID: 37779076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report.
    Zhang Z; Zhang W; Wang H; Hu B; Wang Z; Lu S
    Front Immunol; 2021; 12():744571. PubMed ID: 34603331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report.
    Liu J; Wang C; Cao L; Li S
    Ann Palliat Med; 2020 Mar; 9(2):497-503. PubMed ID: 32233637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab.
    Naganuma A; Sakuda T; Murakami T; Aihara K; Watanuki Y; Suzuki Y; Shibasaki E; Masuda T; Uehara S; Yasuoka H; Hoshino T; Kudo T; Ishihara H; Ogawa T; Kitamoto Y; Ogawa A
    Intern Med; 2020 Sep; 59(18):2261-2267. PubMed ID: 32536644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report.
    Toshida K; Itoh S; Yoshizumi T; Shimagaki T; Wang H; Kurihara T; Toshima T; Nagao Y; Harada N; Oki E; Nakamura Y; Yoshino T; Mori M
    Clin J Gastroenterol; 2021 Oct; 14(5):1459-1463. PubMed ID: 34085164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature.
    Wang Z; Zeng T; Li Y; Zhang D; Yuan Z; Huang M; Yang Y; Zhou W
    Front Immunol; 2021; 12():799822. PubMed ID: 35003124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review.
    Chen WX; Li GX; Hu ZN; Zhu P; Zhang BX; Ding ZY
    Medicine (Baltimore); 2019 Nov; 98(45):e17832. PubMed ID: 31702638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report.
    Nakamura M; Ueno M; Hayami S; Kawai M; Miyamoto A; Suzaki N; Hirono S; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Kojima F; Yamaue H
    Anticancer Res; 2020 Jul; 40(7):4123-4129. PubMed ID: 32620661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of unresectable intrahepatic cholangiocarcinoma receiving sustainable pembrolizumab therapy].
    Matsushita S; Ueo T; Minami R; Ozawa T; Matsumoto A; Kimura Y; Takeda Y; Okano A; Kusumi F; Ohana M
    Nihon Shokakibyo Gakkai Zasshi; 2022; 119(4):360-367. PubMed ID: 35400689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review.
    Liao CX; Deng CS; Liang X; Yang JC; Chen ZZ; Lin XY; Lin CF; Chen S; Wu SS
    Front Immunol; 2023; 14():1239168. PubMed ID: 37753076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma.
    Law LY
    J Clin Oncol; 2012 Sep; 30(27):e271-3. PubMed ID: 22851567
    [No Abstract]   [Full Text] [Related]  

  • 15. Programmed death-1 inhibitor for occupational intrahepatic cholangiocarcinoma caused by chlorinated organic solvents.
    Tanaka S; Kubo S
    J Hepatobiliary Pancreat Sci; 2019 Jun; 26(6):242-243. PubMed ID: 30945442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrahepatic Cholangiocarcinoma With Extrahepatic Metastasis and High Tumor Mutation Burden: Case of Complete Pathological Response to Cisplatin/Gemcitabine/Pembrolizumab.
    Robinson MD; Wheatley R; Foster L; Jamdar S; Siriwardena AK; Lamarca A; Hubner R; Valle JW; McNamara MG
    JCO Precis Oncol; 2024 Apr; 8():e2300572. PubMed ID: 38662981
    [No Abstract]   [Full Text] [Related]  

  • 17. Case report: Preliminary response to tislelizumab plus S-1 in patients with metastatic gallbladder carcinoma: A report of five cases and a literature review.
    Zhang Y; Liu Y; Liu J; Liu T; Xiong H; Li W; Fu X; Zhou F; Liao S; Fang L; Liang B
    Front Immunol; 2023; 14():1144371. PubMed ID: 37020545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report.
    Eguchi S; Shinkawa H; Sato Y; Nakai K; Takemura S; Tanaka S; Amano R; Kimura K; Ohira G; Nishio K; Kinoshita M; Tauchi J; Miyazaki T; Ishihara A; Shirai D; Kubo S
    Clin J Gastroenterol; 2021 Jun; 14(3):858-865. PubMed ID: 33811313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors.
    Zhu S; Bian L; Lv J; Liu B; Shen J
    Front Immunol; 2021; 12():788629. PubMed ID: 35003107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining PD-1 Inhibitor with VEGF/VEGFR2 Inhibitor in Chemotherapy: Report of a Patient with End-Stage Cholangiocarcinoma and Review of Literature.
    Ma Z; Li H; Liu L
    Recent Pat Anticancer Drug Discov; 2021; 16(1):101-107. PubMed ID: 33390149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.